LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Elevance Health Announces Appearance at the 2023 RBC Capital Markets Global Healthcare Conference

May 05, 2023 | Last Trade: US$424.53 10.51 -2.42

INDIANAPOLIS / May 05, 2023 / Business Wire / Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City on May 17, at 8:00 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. Following the presentation, a webcast replay will be available for 90 days.

To listen to the live webcast, please visit Elevance Health’s website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Elevance Health’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2022.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page